Strauss G M
Division of Hematology/Oncology, Worcester-Memorial Hospital, Massachusetts.
Hematol Oncol Clin North Am. 1997 Jun;11(3):409-34. doi: 10.1016/s0889-8588(05)70441-x.
Numerous prognostic factors have been identified in patients with resectable non-small cell lung cancer (NSCLC) which may enable stratification of patients into subsets indicating risk of recurrence following complete resection. Such prognostic markers include a variety of clinico-pathologic factors such as tumor size, modal status, and histopathologic variables. Several serum tumor markers have also proven useful. Moreover, a wide variety of molecular markers have been described over the last decade, which can be classified as molecular genetic markers, metastatic propensity markers, differentiation markers, and proliferation markers. This article reviews those prognostic markers most likely to prove clinically useful from the perspective of guiding postresection treatment strategies in early stage NSCLC.
在可切除的非小细胞肺癌（NSCLC）患者中已确定了许多预后因素，这些因素可将患者分层为不同亚组，提示完全切除后复发风险。此类预后标志物包括多种临床病理因素，如肿瘤大小、模态状态和组织病理学变量。几种血清肿瘤标志物也已证明有用。此外，在过去十年中描述了各种各样的分子标志物，可分为分子遗传标志物、转移倾向标志物、分化标志物和增殖标志物。本文从指导早期NSCLC切除后治疗策略的角度，综述那些最有可能证明具有临床实用性的预后标志物。
